ReviewFrontiers in endocrinology2014
Spermatogenesis and cryptorchidism.
Review in Frontiers in endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 81 citations in OpenAlex.
- Can we predict which cryptorchidism will descend? A cohort study in 976 Korean neonates.Investigative and clinical urology · 2026Article
- Orchiopexy age and testicular catch-up growth in unilateral cryptorchidism: a retrospective cohort study.European journal of pediatrics · 2026Article
- Epidemiology, Etiopathogenesis, Diagnosis, and Treatment of Male Infertility-Current Trends and Future Directions: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Cryptorchidism and infertility: what do we know so far?Asian journal of andrology · 2026Review
- Seminal Plasma Metabolomic Profiling Reveals Key Metabolic Signatures Linked to Spermatogenic Potential in Non-Obstructive Azoospermia with Cryptorchidism.Metabolites · 2026Article
- Bilateral testicular atrophy and hypogonadism induced by paratesticular leiomyosarcoma and untreated cryptorchidism.Urology case reports · 2025Article
- Review
- Ferroptotic- and non-ferroptotic mechanisms associated with doxorubicin-induced male reproductive dysfunction.Toxicology reports · 2025Review
- Decoding the Puzzle of Male Infertility: The Role of Infection, Inflammation, and Autoimmunity.Diagnostics (Basel, Switzerland) · 2025Review
- Abnormal H3K27me3 underlies degenerative spermatogonial stem cells in cryptorchid testis.Development (Cambridge, England) · 2025Article
- Short-Term Treatment of Melatonin Improves the Expression of Cell Adhesion Molecules in the Testis of the Mouse Cryptorchidism Model.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2024Article
- Mini-Puberty, Physiological and Disordered: Consequences, and Potential for Therapeutic Replacement.Endocrine reviews · 2024Review
- Evaluation of testicular stiffness in boys with unilateral cryptorchidism after orchiopexy by ultrasound strain elastography.Fukushima journal of medical science · 2024Article
- Downregulation of Serotonergic System Components in an Experimentally Induced Cryptorchidism in Rabbits.International journal of molecular sciences · 2024Article
- Trpv4-mediated apoptosis of Leydig cells induced by high temperature regulates sperm development and motility in zebrafish.Communications biology · 2024Article
- Advantages of single-site laparoscopic orchiopexy for palpable undescended testes in children: a prospective comparison study.Pediatric surgery international · 2024Article
- Surgical treatment of cryptorchidism: current insights and future directions.Frontiers in endocrinology · 2024Review
- Article
- Laparoscopic totally extraperitoneal exploration of intra-abdominal testis, orchidectomy and inguinal hernia repair in an adult patient.BMJ case reports · 2023Article
- Genome-Wide Association Screening Determines Peripheral Players in Male Fertility Maintenance.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptorchidism represents the most common endocrine disease in boys, with infertility more frequently observed in bilateral forms. It is also known that undescended testes, if untreated, lead to an increased risk of testicular tumors, usually seminomas, arising from mutant germ cells. In normal testes, germ cell development is an active process starting in the first months of life when the neonatal gonocytes transform into adult dark (AD) spermatogonia. These cells are now thought to be the stem cells useful to support spermatogenesis. Several researches suggest that AD spermatogonia form between 3 and 9 months of age. Not all the neonatal gonocytes transform into AD spermatogonia; indeed, the residual gonocytes undergo involution by apoptosis. In the undescended testes, these transformations are inhibited leading to a deficient pool of stem cells for post pubertal spermatogenesis. Early surgical intervention in infancy may allow the normal development of stem cells for spermatogenesis. Moreover, it is very interesting to note that intra-tubular carcinoma in situ in the second and third decades have enzymatic markers similar to neonatal gonocytes suggesting that these cells fail transformation into AD spermatogonia and likely generate testicular cancer (TC) in cryptorchid men. Orchidopexy between 6 and 12 months of age is recommended to maximize the future fertility potential and decrease the TC risk in adulthood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.